Loading...
Detection of early tumor response to axitinib in advanced hepatocellular carcinoma by dynamic contrast enhanced ultrasound.
Lo, G Al Zahrani, H Jang, H Menezes, R Hudson, J Burns, P McNamara, Mairéad G Kandel, S Khalili, K Knox, J
Lo, G
Al Zahrani, H
Jang, H
Menezes, R
Hudson, J
Burns, P
McNamara, Mairéad G
Kandel, S
Khalili, K
Knox, J
Citations
Altmetric:
Abstract
This study aimed to evaluate the utility of dynamic contrast-enhanced ultrasound (DCE-US) in measuring early tumor response of advanced hepatocellular carcinoma to axitinib. Twenty patients were enrolled (aged 18-78 y; median 65). DCE-US was performed with bolus injection and infusion/disruption replenishment. Median overall survival was 7.1 mo (1.8-27.3) and progression free survival was 3.6 mo (1.8-17.4). Fifteen patients completed infusion scans and 12 completed bolus scans at 2 wk. Among the perfusion parameters, fractional blood volume at infusion (INFBV) decreased at 2 wk in 10/15 (16%-81% of baseline, mean 47%) and increased in 5/15 (116%-535%, mean 220%). This was not significantly associated with progression free survival (p = 0.310) or progression at 16 wk (p = 0.849), but was borderline statistically significant (p = 0.050) with overall survival, limited by a small sample size. DCE-US is potentially useful in measuring early tumor response of advanced hepatocellular carcinoma to axitinib, but a larger trial is needed.
Affiliation
Description
Date
2016-03-28
Publisher
Collections
Keywords
Type
Article
Citation
Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound. 2016: Ultrasound Med Biol